Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value
-
Shares outstanding
-
83.1M
-
Number of holders
-
34
-
Total 13F shares, excl. options
-
1.78M
-
Shares change
-
+1.78M
-
Total reported value, excl. options
-
$9.12M
-
Value change
-
+$9.11M
-
Put/Call ratio
-
0.05
-
Number of buys
-
32
-
Price
-
$5.11
Significant Holders of Checkpoint Therapeutics, Inc. - Common Stock, $0.0001 Par Value (CKPT) as of Q4 2022
36 filings reported holding CKPT - Checkpoint Therapeutics, Inc. - Common Stock, $0.0001 Par Value as of Q4 2022.
Checkpoint Therapeutics, Inc. - Common Stock, $0.0001 Par Value (CKPT) has 34 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.78M shares
of 83.1M outstanding shares and own 2.15% of the company stock.
Largest 10 shareholders include ARMISTICE CAPITAL, LLC (692K shares), VANGUARD GROUP INC (302K shares), BANK OF AMERICA CORP /DE/ (202K shares), BlackRock Inc. (95.9K shares), GEODE CAPITAL MANAGEMENT, LLC (71.6K shares), PVG ASSET MANAGEMENT CORP (55K shares), Royal Bank of Canada (48.2K shares), PARK AVENUE SECURITIES LLC (46.5K shares), MILLENNIUM MANAGEMENT LLC (36.9K shares), and ADVISOR GROUP HOLDINGS, INC. (34.2K shares).
This table shows the top 34 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.